[REVISION HISTORY]

Perimenopause health: metabolic, cardiovascular, and brain

Updated 22 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-30 11:44 UTC → 2026-10-02 09:48 UTC · added ~~removed~~

Research continues to link perimenopausal hormonal shifts to diverse metabolic, musculoskeletal, and sexual changes. Declining estrogen and fluctuating progesterone, testosterone, cortisol, and thyroid hormones disrupt hair growth, accelerate sarcopenia, and alter skin and oral tissue integrity. Metabolic impacts include midlife weight gain—averaging 0.8 kg per year—and increased visceral fat, which raises risks for inflammation, heart disease, type 2 diabetes, stroke, and dementia. Recent findings emphasize the cardiovascular and neurological risks associated with the menopausal transition. Data shared by the North American Menopause Society indicates that the risk of hypertension increases as the age of menopause decreases. Cardiologists warn that the transition can lead to increased cholesterol, higher blood pressure, and abdominal fat accumulation, favoring atherosclerosis. In Brazil, the Brazilian Society of Cardiology notes that cardiometabolic diseases are often underdiagnosed in women, and cardiovascular disease remains a leading cause of death, surpassing cancer. Notably, heart attack symptoms in women may present as stomach pain, nausea, extreme fatigue, or cold sweats rather than traditional chest pain. Experts suggest mitigating these risks through 150 minutes of weekly aerobic activity combined with resistance training. A study in Nature Medicine involving approximately 15,000 women identified molecular changes in the blood that correlate with brain aging and cognitive decline. ~~These modifications in inflammatory, synaptic, and metabolic processes appear more closely related to hormonal shifts than chronological age, suggesting a link to Alzheimer’s disease.~~ Regarding treatment, a large Danish observational study published in the British Medical Journal ~~analyzed data from over one million women. It~~ found that oral hormone replacement therapy (HRT) is associated with an average 60 percent higher risk of venous thrombosis compared to ~~non-users, a~~ non-users. Newer research highlights the role of estrone, which becomes more dominant after menopause and may increase the risk and aggressiveness of certain breast cancers by promoting inflammation. Additionally, experts note that ~~remains consistent regardless~~ changes in sexual desire are driven by a complex mix of ~~dosage or duration.~~ hormonal shifts, physical discomfort like vaginal dryness, and psychological factors such as stress, sleep quality, and mental load.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.